Compare DraftKings Inc (DKNG) vs Summit Therapeutics Inc (SMMT) Price & Performance

DraftKings (DKNG) trades at $19.43, down 1.46% on the day and near 52-week lows. The technical picture is bearish with weak moving averages, while fundamentals show strong revenue growth to $6.05B in 2025 but negative profitability metrics. Recent earnings misses and high valuation multiples create headwinds, though analyst sentiment remains overwhelmingly bullish with a $33.13 price target.

The stock faces near-term pressure from technical weakness and earnings volatility, but long-term prospects are supported by market share leadership and prediction platform expansion. Key risks include competitive threats, regulatory uncertainty, and the sustainability of current valuation levels amid profitability challenges.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.